Compare HII & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HII | KRYS |
|---|---|---|
| Founded | 1886 | 2015 |
| Country | United States | United States |
| Employees | 44000 | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 9.6B |
| IPO Year | 2010 | 2017 |
| Metric | HII | KRYS |
|---|---|---|
| Price | $297.57 | $345.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $411.33 | $297.60 |
| AVG Volume (30 Days) | ★ 542.2K | 508.3K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | 10.24 | ★ 128.00 |
| EPS | ★ 9.06 | 3.62 |
| Revenue | ★ $12,484,000,000.00 | $389,130,000.00 |
| Revenue This Year | $4.82 | $38.74 |
| Revenue Next Year | $6.28 | $32.53 |
| P/E Ratio | ★ $33.27 | $93.10 |
| Revenue Growth | 8.23 | ★ 33.94 |
| 52 Week Low | $263.62 | $143.09 |
| 52 Week High | $460.00 | $382.54 |
| Indicator | HII | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 42.07 | 54.09 |
| Support Level | $294.50 | $253.89 |
| Resistance Level | $299.84 | $382.33 |
| Average True Range (ATR) | 8.38 | 10.03 |
| MACD | -3.41 | 1.62 |
| Stochastic Oscillator | 2.66 | 98.36 |
Huntington Ingalls Industries is the largest independent military shipbuilder in the US, spun out from Northrop Grumman in 2011. It operates three segments, two of which are storied shipyards: Ingalls produces non-nuclear-powered ships, including amphibious landing ships and Arleigh Burke-class destroyers, while Newport News produces nuclear-powered ships as the only producer of Gerald Ford-class aircraft carriers and a major subcontractor on Virginia- and Columbia-class nuclear submarines. HII shares production of destroyers and nuclear submarines with General Dynamics' Bath Iron Works and Electric Boat shipyards, respectively. The company's mission technologies segment produces uncrewed sea vessels and provides a range of IT and other services to US government agencies.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.